Max Higgins, Senior Consultant, Author at EverGlade - Page 6 of 11

Max Higgins, Senior Consultant

Max Higgins, Senior Consultant

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates

As the global health landscape evolves, so too must the United States’ ability to respond rapidly to biological threats. To strengthen its readiness posture, the Biomedical Advanced Research and Development Authority (BARDA), in coordination with the Administration for Strategic Preparedness and Response (ASPR), has released a new opportunity under the BioMaP Consortium OT Vehicle. This […]

BARDA’s Onshoring of Viral Hemorrhagic Fevers Vaccine Candidates Read More »

DARPA NODES

DARPA Launches NODES to Revolutionize Protein Function Prediction

DARPA-PS-25-30 Program Solicitation Network of Optimal Dynamic Energy Signatures (NODES) On July 31, 2025, the Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), released a new program solicitation titled Network of Optimal Dynamic Energy Signatures (NODES). This initiative seeks to unlock a deeper understanding of protein functions by moving beyond static

DARPA Launches NODES to Revolutionize Protein Function Prediction Read More »

DTRA RAVEN Program

DTRA’s Reimagining the Next Generation of Biodefense Vaccines

Reimagining the Next Generation of Biodefense Vaccines: DTRA’s RAVEN Opportunity The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO) and the Research and Development-Chem/Bio Medical Vaccines (RD-CBMV) division, has launched the Reimagining Available Vaccines and Envisioning Novelty (RAVEN) initiative. This forward-looking program is designed to modernize the nation’s medical countermeasure

DTRA’s Reimagining the Next Generation of Biodefense Vaccines Read More »

JPEO RFI u.s. military protective systems

U.S. Army Seeks Breakthrough Concepts to Combat Contaminant Infiltration in Protective Systems

Overview In a Request for Information (RFI), the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Protection (JPM CBRN P), has called on industry, academia, and non-traditional innovators to help reimagine how protective gear prevents the infiltration of harmful airborne particles and vapors. This initiative aims to address a longstanding issue known as the

U.S. Army Seeks Breakthrough Concepts to Combat Contaminant Infiltration in Protective Systems Read More »

protein moecules

DARPA’s NODES Program to Decode the Protein Universe Through AI and Biophysics

The Defense Advanced Research Projects Agency (DARPA) has launched a new initiative to advance the understanding of protein molecular function based on sequence and structural data. With over 300 million protein sequences and structures cataloged, but only 1% functionally characterized, DARPA’s Network of Optimal Dynamic Energy Signatures (NODES) program seeks to transform our ability to

DARPA’s NODES Program to Decode the Protein Universe Through AI and Biophysics Read More »

Enzyme structure with biological concept 3d rendering

BARDA Solicits Enzymatic Debridement Solutions

BARDA RFP – Enzymatic Debridement Products for Treatments of Deep and Full- Thickness Severe Burn Injuries – 75A50125R00007 – Amendment 0001 The Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), has released a significant new opportunity to strengthen national preparedness for burn mass casualty

BARDA Solicits Enzymatic Debridement Solutions Read More »

Biothreat Pathogens

BARDA Launches RFP for vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV)

BARDA RFP – Marburg Virus and Sudan Ebolavirus Vaccine Licensure and Procurement On July 12, 2025, the Biomedical Advanced Research and Development Authority (BARDA) issued Request for Proposals (RFP) #75A50125R00006. This RFP seeks proposals for the advanced development, FDA licensure, and procurement of vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV). With recent outbreaks

BARDA Launches RFP for vaccines targeting Marburg virus (MARV) and Sudan ebolavirus (SUDV) Read More »

Close up of blue antibiotic capsules

BARDA Launches New RFP to Bolster Antibiotic Stockpiles Against Drug-Resistant and Biothreat Pathogens

Request for Proposals (RFP) for Antibiotic for Treatment of Bacterial Pneumonia or Bloodstream Infections Bolstering Biodefense with Advanced Antibiotics: BARDA’s Strategic Move As the threat of antibiotic-resistant infections intensifies, the U.S. Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has issued a pivotal solicitation under Project BioShield

BARDA Launches New RFP to Bolster Antibiotic Stockpiles Against Drug-Resistant and Biothreat Pathogens Read More »

Blue digitally distorted brain illustration

ARPA-H Announces the Functional Repair of Neocortical Tissue (FRONT) Program

Functional Repair of Neocortical Tissue (FRONT) Health Science Futures (HSF) Innovative Solutions Opening (ISO) ARPA-H-SOL-25-120 July 10, 2025 Restoring the Damaged Brain: ARPA-H’s FRONT Program Targets Functional Neocortical Repair The Advanced Research Projects Agency for Health (ARPA-H) has announced an ambitious new program under its Health Science Futures (HSF) office: the Functional Repair of Neocortical

ARPA-H Announces the Functional Repair of Neocortical Tissue (FRONT) Program Read More »

Cortisol molecule

DARPA’s CoasterChase Initiative

CoasterChase – BIOLOGICAL TECHNOLOGIES OFFICE – HR001125S0014 Targeting Stress from the Inside Out: DARPA’s CoasterChase Initiative The Defense Advanced Research Projects Agency (DARPA) continues to push the boundaries of biomedical technology with the release of its latest Broad Agency Announcement (BAA), HR001125S0014, titled CoasterChase. Issued by DARPA’s Biological Technologies Office (BTO), this program seeks to

DARPA’s CoasterChase Initiative Read More »

enzymatic debridement product

BARDAs Strategic Investment in Enzymatic Debridement Products

Advancing Burn Care Preparedness: BARDA’s Strategic Investment in Enzymatic Debridement Products In its ongoing mission to strengthen the nation’s biodefense and emergency response infrastructure, the Biomedical Advanced Research and Development Authority (BARDA), an office within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, has released a

BARDAs Strategic Investment in Enzymatic Debridement Products Read More »

Transparent ampules on a blue background

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections

Combating Resistant Infections: BARDA’s Push for Advanced Antibiotics The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), has released a pre-solicitation notice aimed at identifying qualified vendors to support the late-stage development, procurement, and stockpiling of antibiotics for critical public health threats. Targeted programs include

BARDA’s Call to Action Antibiotics for Treatment of Bacterial Pneumonia or Bloodstream Infections Read More »

Scroll to Top